Bendamustine plus rituximab for indolent B‐cell lymphoma of renal significance

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|3|356-362

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.3, 2018-03, pp. : 356-362

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab

By  

Acta Haematologica, Vol. 126, Iss. 1, 2011-03 ,pp. : 40-43

Karger

Access to resources Recommend Favorite

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

By  

Case Reports in Oncology, Vol. 5, Iss. 2, 2012-08 ,pp. : 413-419

Karger

Access to resources Recommend Favorite

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 497-502

Karger

Access to resources Recommend Favorite

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 188-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab

By  

Acta Haematologica, Vol. 130, Iss. 2, 2013-03 ,pp. : 74-82

Karger

Access to resources Recommend Favorite